Defining high, medium and low impact prognostic factors for developing multiple sclerosisMar Tintoré, Xavier Montalbán, Àlex Rovira et al.|Brain|2015Cited by 520
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsJordi Río, Xavier Montalbán, Carlos Nos et al.|Annals of Neurology|2006Cited by 327
Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?N. Téllez, Xavier Montalbán, Jordi Río et al.|Multiple Sclerosis Journal|2005Cited by 294
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisCarmen Tur, Xavier Montalbán, Susana Otero‐Romero et al.|JAMA Neurology|2022Cited by 278
The value of oligoclonal bands in the multiple sclerosis diagnostic criteriaGeorgina Arrambide, Xavier Montalbán, Mar Tintoré et al.|Brain|2018Cited by 158